UNLABELLED: Twenty-eight patients (12 men with prostate cancer, 16 women with breast cancer) were included in a phase II trial to evaluate the efficacy of 186Re-hydroxyethylidene diphosphonate (HEDP) on pain from bone metastasis and the toxicity of this agent. METHODS: After intravenous administration of 1295 MBq 186Re-HEDP, the efficacy was evaluated by means of a daily log. RESULTS: We observed an objective response in 67% of prostate cancer patients and in 36% of breast cancer patients. The mean duration of response was 45 d for prostate cancer patients and 24 d for breast cancer patients. No major adverse effects were observed. Marrow toxicity did not exceed grade 2 for white blood cells and grade 3 for platelets using National Cancer Institute criteria. CONCLUSION: 186Re-HEDP provides safe symptomatic relief of pain in prostate cancer patients. The benefit of this treatment is less clear in breast cancer patients. Further studies should be conducted to evaluate treatment by 186Re-HEDP at an earlier stage of the disease.
UNLABELLED: Twenty-eight patients (12 men with prostate cancer, 16 women with breast cancer) were included in a phase II trial to evaluate the efficacy of 186Re-hydroxyethylidene diphosphonate (HEDP) on pain from bone metastasis and the toxicity of this agent. METHODS: After intravenous administration of 1295 MBq 186Re-HEDP, the efficacy was evaluated by means of a daily log. RESULTS: We observed an objective response in 67% of prostate cancerpatients and in 36% of breast cancerpatients. The mean duration of response was 45 d for prostate cancerpatients and 24 d for breast cancerpatients. No major adverse effects were observed. Marrow toxicity did not exceed grade 2 for white blood cells and grade 3 for platelets using National Cancer Institute criteria. CONCLUSION: 186Re-HEDP provides safe symptomatic relief of pain in prostate cancerpatients. The benefit of this treatment is less clear in breast cancerpatients. Further studies should be conducted to evaluate treatment by 186Re-HEDP at an earlier stage of the disease.
Authors: Ana M Denis-Bacelar; Sarah J Chittenden; David P Dearnaley; Antigoni Divoli; Joe M O'Sullivan; V Ralph McCready; Bernadette Johnson; Yong Du; Glenn D Flux Journal: Eur J Nucl Med Mol Imaging Date: 2016-10-21 Impact factor: 9.236
Authors: J M O'Sullivan; V R McCready; G Flux; A R Norman; F M Buffa; S Chittenden; M Guy; K Pomeroy; G Cook; J Gadd; J Treleaven; A Al-Deen; A Horwich; R A Huddart; D P Dearnaley Journal: Br J Cancer Date: 2002-06-05 Impact factor: 7.640